MENU × BUSINESS
Banking And InsuranceCryptocurrencyDigital MarketingErpFood And BeveragesHealthcareLegalMarketing And AdvertisingMedia And EntertainmentMetals And MiningOil And GasRetailTelecom
TECHNOLOGY
Artificial IntelligenceBig DataCloudCyber SecurityE CommerceEducationGaming And VfxIT ServiceMobileNetworkingSAPScience And TechnologySecuritySoftwareStorage
PLATFORM
CiscoDatabaseGoogleIBMJuniperM2MMicrosoftOracleOracleRed Hat
LEADERSHIP
CEO ReviewCompany Review
MAGAZINE
ASIA INDIA
STARTUPS CLIENT SPEAK CONTACT US

The Silicon Review Asia

Sun Pharma signs a formal agreement with AstraZeneca to develop cancer-related drugs

Sun Pharma signs a formal agreement with AstraZeneca to develop cancer-related drugs

Sun Pharma has signed a new agreement with AstraZeneca to develop and distribute cancer/oncology-related drugs to China. A recent report stated that the Indian generic pharmaceutical giant Sun Pharma with AstraZeneca is all set to produce anti-cancer drugs. It also said that Sun Pharma will be taking care of development, regulatory filings, and manufacturing of the products. AstraZeneca will be exclusively responsible for promoting and distributing these products in China.

Sun Pharmaceutical Industries Ltd has also entered into a licensing agreement with AstraZeneca UK Ltd to introduce certain novel and unique ready-to-use infusion oncology and anti-cancerous products for cancer patients in China. The initial time/tenure of the agreement is said to be for 10 years from the day of first commercial sale of the developed products in China, but the financial terms and conditions of the agreement are kept confidential.

“We see a great potential to introduce our specialty and generics products in the growing China market and this licensing agreement is another positive step in that direction,"stated Kal Sundaram, director of corporate development at Sun Pharma, was quoted as saying in the release.

This agreement will help bring cheap and cost-effective drugs to cancer patients in China. The drug quality will be improved, and also will help both the firms to gain popularity and large market value in countries like Asia, Asian-Pacific, and other European countries in the coming time.

YOU MAY ALSO LIKE

Tariff plans will cost higher from the next financial year as telecom companies are gearing up to increase rates

The ongoing Covid pandemic had significantly increased the number of mobile and internet users worldwide. The high amount of usage is expected to drop...

Business Travelers to Stay at Singapore’s Changi Airport Bubble

Singapore’s open economy depends heavily on tourism and business. But its vibrant but small economy has been hurting as the circumstances due to...

Countries in Asia-Pacific are marching towards ‘green recovery’ amidst Covid-19 crisis

2020 has been an unforgettable year for many of us. The ongoing Covid crisis has reminded people that it is very important to have an uninterrupted an...

Department of Telecommunication to announce the new schedule for 5G trials

Department of Telecommunications (DoT) is all set to announce the new schedule for 5G trials. The Dot made this decision after being pulled by the par...

RECOMMENDED